$40MVenture, 8 April 2026
Funds completion of Phase 2 STAR trial in HIE and FDA end-of-Phase 2 meeting.
- Amount
- $40M
- Stage
- Venture
- Announced
- 8 April 2026
- Use of funds
- Funds completion of Phase 2 STAR trial in HIE and FDA end-of-Phase 2 meeting.
- Checked
- Announced by the company
- Sources
- ReAlta Life Sciences closes oversubscribed $40M financing businesswire.com
ReAlta Life Sciences closes oversubscribed $40M financing pulse2.com